Colchicine
(Synonyms: 秋水仙碱) 目录号 : GC13261
Colchicine（秋水仙碱）是一种可口服的生物碱，通过抑制β-微管蛋白聚合成微管来破坏细胞骨架功能，Colchicine抑制微管的IC50为3 nM。
Cas No.:64-86-8
Sample solution is provided at 25 µL, 10mM.
Colchicine, an orally active alkaloid, disrupts cytoskeletal function by inhibiting the polymerization of β-tubulin into microtubules, with an IC50 of 3 nM. Additionally, colchicine acts as a competitive antagonist of the α3 glycine receptor (GlyR) [1]. Colchicine exhibits a broad spectrum of anti-inflammatory, immunosuppressive, and potent anti-fibrotic effects, making it effective in controlling gout and reducing the risk of cardiovascular events [2-3].
Colchicine(10 nM; 1h) prevented foam cell formation induced by ox-LDL in macrophages differentiated from human THP-1 cells[4]. Colchicine (1 nM; 24h) treatment diminished GSK-3β phosphorylation and β-catenin translocation to the nucleus in cultured human aortic SMCs exposed to PDGF-BB stimulation[5].
Colchicine (0.102 mg/kg; 12 weeks; i.g) demonstrates anti-atherosclerotic and plaque-stabilizing effects at low doses by inhibiting foam cell formation and reducing cholesterol crystal-induced inflammation[4]. Colchicine (0.1 mg/kg/d; i.p.; 2 weeks) can restrict abdominal aortic aneurysm (AAA) formation by preventing the infiltration of immune cells into the aortic wall[6]. Colchicine inhibits the activation of the NLRP3 inflammasome, thereby preventing small intestine damage induced by non-steroidal anti-inflammatory drugs (NSAIDs)[7].
References:
[1]. Muñoz-Montesino C, Burgos CF, et,al. Inhibition of the Glycine Receptor alpha 3 Function by Colchicine. Front Pharmacol. 2020 Jul 30;11:1143. doi: 10.3389/fphar.2020.01143. PMID: 32903667; PMCID: PMC7438739.
[2]. McKenzie BJ, Wechalekar MD, et,al. Colchicine for acute gout. Cochrane Database Syst Rev. 2021 Aug 26;8(8):CD006190. doi: 10.1002/14651858.CD006190.pub3. PMID: 34438469; PMCID: PMC8407279.
[3]. Zhang FS, He QZ, et,al.Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review. Acta Pharmacol Sin. 2022 Sep;43(9):2173-2190. doi: 10.1038/s41401-021-00835-w. Epub 2022 Jan 19. PMID: 35046517; PMCID: PMC8767044.
[4]. Schwarz N, Fernando S, et,al. Colchicine exerts anti-atherosclerotic and -plaque-stabilizing effects targeting foam cell formation. FASEB J. 2023 Apr;37(4):e22846. doi: 10.1096/fj.202201469R. PMID: 36856983.
[5]. Chen M, Yang D, et,al. Colchicine Blocks Abdominal Aortic Aneurysm Development by Maintaining Vascular Smooth Muscle Cell Homeostasis. Int J Biol Sci. 2024 Mar 17;20(6):2092-2110. doi: 10.7150/ijbs.93544. PMID: 38617538; PMCID: PMC11008260.
[6]. Zhao Y, Shen QR, et,al. Colchicine protects against the development of experimental abdominal aortic aneurysm. Clin Sci (Lond). 2023 Oct 11;137(19):1533-1545. doi: 10.1042/CS20230499. PMID: 37748024; PMCID: PMC10550771.
[7]. Otani K, Watanabe T, et,al. Colchicine prevents NSAID-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Sci Rep. 2016 Sep 2;6:32587. doi: 10.1038/srep32587. PMID: 27585971; PMCID: PMC5009328.
Colchicine（秋水仙碱）是一种可口服的生物碱，通过抑制β-微管蛋白聚合成微管来破坏细胞骨架功能，Colchicine抑制微管的IC50为3 nM。Colchicine也是α3甘氨酸受体(GlyR)的竞争性拮抗剂[1]。Colchicine具有广泛的抗炎、免疫抑制和强抗纤维化作用，可用于控制痛风，降低心血管疾病风险[2-3]。
Colchicine (10 nM; 1h)抑制ox-LDL诱导（从人THP-1细胞分化的）巨噬细胞分化形成泡沫细胞 [4]。Colchicine (1 nM; 24h)减少了在PDGF-BB刺激下的人主动脉SMCs中GSK-3β磷酸化和β-catenin核易位[5]。
Colchicine (0.102 mg/kg; 12weeks; i.g)通过抑制泡沫细胞形成和胆固醇晶体诱导的炎症，在低剂量下发挥抗动脉粥样硬化和稳定斑块的作用[4]。Colchicine (0.1 mg/kg/d; i.p.; 2 weeks) 可以通过阻止免疫细胞浸润到主动脉壁来限制腹主动脉瘤(AAA)的形成[6]。Colchicine可抑制NLRP3炎性体的激活来预防非甾体抗炎药(NSAID)诱导的小肠损伤[7]。
| Cell experiment [1]: | |
Cell lines | MDMs (Human monocyte-derived macrophages) differentiated from human THP-1 cells |
Preparation Method | For studying human ORO foam cell formation, MDMs were initially treated for 1 hour with colchicine (10 nM), vinblastine (10 nM), or paclitaxel (100 nM), and subsequently exposed to ox-LDL as described previously. |
Reaction Conditions | 10 nM; 1h |
Applications | Colchicine prevented foam cell formation induced by oxidized LDL (ox-LDL) in macrophages differentiated from human THP-1 cells. |
| Animal experiment [2]: | |
Animal models | C57BL / 6J Apoe−/− mice |
Preparation Method | Mice were fed an atherogenic high-cholesterol diet (HCD) containing 0.15% cholesterol and 21% fat for 16 weeks, starting at 8 weeks of age. In the fourth week, they were randomly assigned to receive either phosphate-buffered saline (PBS) or colchicine at 0.102 mg/kg via daily oral gavage for 12 weeks. |
Dosage form | 0.102 mg/kg; 12weeks; i.g |
Applications | Colchicine reduces lipidic atherosclerotic plaques in mouse aorta. |
References: | |
| Cas No. | 64-86-8 | SDF | |
| 别名 | 秋水仙碱 | ||
| 化学名 | N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide | ||
| Canonical SMILES | CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC | ||
| 分子式 | C22H25NO6 | 分子量 | 399.44 |
| 溶解度 | ≥ 19.972 mg/mL in DMSO, ≥ 50.8 mg/mL in EtOH with gentle warming, ≥ 45.5 mg/mL in Water with gentle warming | 储存条件 | Store at 4°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5035 mL | 12.5175 mL | 25.035 mL |
| 5 mM | 0.5007 mL | 2.5035 mL | 5.007 mL |
| 10 mM | 0.2504 mL | 1.2518 mL | 2.5035 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet